Telehealth remains underused, patients rarely billed for messages

To pursue reimbursement for telehealth services, or patient “e-visits,” providers have begun billing insurers and patients for interactions through patient portals. However, remote patient care and associated patient portal messages are either rarely billed to Medicare or rarely occur, as these practices make up a very small percentage of services submitted for reimbursement. The findings are published in Health Affairs Scholar. [1]

In 2020, e-visits comprised 0.9% of all managed service codes submitted to Medicare at the height of the pandemic, dropping to 0.5% in 2021 and 2022. During that timeframe, only 0.8% of all fee-for-service Medicare beneficiaries were billed for a patient portal message, despite the fact they can stem from both in-person and virtual visits.

The study shows telehealth still remains underutilized, and its findings can “help alleviate concerns regarding the potential overuse of portal message and e-visit billing," the study authors, led by Terrence Liu, MD, of Sutter Health, wrote. However, the research is incomplete, as the authors lacked access to numbers reflecting the total number of e-visits or messages sent through patient portals, many of which may not have been billed or recorded.

Details on patient communications may not have been recorded because of disparate or inadequate technology at provider practices, combined with relaxed regulation during the pandemic that allowed for consumer-level tools to be used to interact with patients. 

Perhaps unsurprisingly, of patient messages billed to Medicare, nearly a third required significant provider time to read or respond to—upwards of 21 minutes. Primary care providers were the most likely to charge a patient for messages, as they comprise more than half of all telehealth and e-visits. 

While patients leveraged e-visits for a variety of reasons—especially when in-person visits were challenged by the pandemic—hypertension was the number one patient diagnosis, recorded at 21% of all care incidents. Diabetes and COVID-19 were distant seconds at around 2% of diagnoses each. 

The full study findings are available at the link below.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.